[ESAB] ESAB Corporation Thesis 2026: Recurring Welding Consumables and a Lean Operating System Drive Margins Higher

Key Takeaways

• ESAB Corporation (NYSE: ESAB) is expected to close FY2025 with selected various aggregate revenue of roughly $2.6-2.95B and aggregate adjusted EPS in the area of $5.00-6.25, with adjusted EBITDA around ~$490-570M (~18-20%+ margin, expanding), under President & CEO Shyam Kambeyanda (~3-4 year tenure since the April 2022 spin-off from Enovis/Colfax).
• The first deep-dive — Welding & Cutting (Equipment plus Consumables) — is the core fabrication-technology franchise: welding power sources, automation and cutting systems plus, crucially, filler metals (welding wire, electrodes, fluxes) — a recurring, high-margin consumables stream that is roughly half-ish of revenue and tracks fabrication activity; FY2026 catalyst is global industrial/construction/energy demand, pricing, and the equipment/automation refresh cycle.
• The second deep-dive — Gas Control plus the EBX operating system and M&A — covers the gas-equipment business (regulators, manifolds, cutting/welding gas apparatus under the GCE brand, plus a growing specialty/medical-gas adjacency built via acquisitions like Ohio Medical and Sager), the "ESAB Business Excellence" (EBX) lean-operating system that has been driving structural margin expansion, and the disciplined bolt-on M&A program; FY2026 catalyst is Gas Control growth (especially medical/specialty gas), EBX-driven margin gains, and accretive acquisitions.
• Capital position is steadily de-levering: a small dividend (selected various aggregate ~$0.30-0.40/share, a ~0.1-0.3% yield), opportunistic buybacks, selected various aggregate net debt in the area of $0.6-1.2B, roughly ~1.0-2.5x net debt/EBITDA (down sharply since the spin), a near-investment-grade credit profile, and roughly ~60M shares outstanding.
• FY2026 catalysts: the global fabrication/industrial cycle and emerging-market demand (a large share of revenue), pricing/cost spread, the consumables recurring base, Gas Control and medical-gas expansion, EBX-driven margin progression, bolt-on M&A, continued de-leveraging, and free-cash-flow generation.

Company Background

ESAB Corporation, headquartered in North Bethesda, Maryland, is a global leader in fabrication technology — welding and cutting equipment and consumables — and gas-control equipment. ESAB ("Elektriska Svetsnings-Aktiebolaget") is one of the oldest names in welding, founded in Sweden in 1904 by the inventor of the coated welding electrode; it became part of Charter International, then of Colfax Corporation (which bought Charter in 2012). In April 2022 Colfax split into two public companies — Enovis (the medical-technology business, which kept the Colfax/ESAB legacy "Colfax" entity renamed) and ESAB Corporation (this entity, the fabrication-technology and gas-control business) — spinning ESAB off as a standalone, with Shyam Kambeyanda as President & CEO. ESAB reports two segments by geography — Americas and EMEA & APAC — and within each it sells three product groups: Equipment (welding power sources, wire feeders, plasma and oxy-fuel cutting systems, robotic/automated welding cells, digital welding-management software), Consumables (filler metals — solid and flux-cored welding wire, stick electrodes, fluxes, brazing alloys — the recurring, high-margin core, roughly half-ish of revenue) and Gas Control (pressure regulators, flowmeters, manifolds, cutting and welding gas apparatus, and a growing specialty- and medical-gas-equipment line, marketed largely under the GCE Group brand). End-markets span general fabrication, construction and infrastructure, energy (oil & gas, pipelines, power, wind), transportation, shipbuilding, repair & maintenance, and (via medical gas) healthcare. Geography is genuinely global, with a large share of revenue from emerging markets (Latin America, the Middle East, India, Asia, Eastern Europe) — a structural growth tailwind but also a source of currency and macro volatility. The capital structure carried meaningful leverage at the spin and has been steadily reduced; capital allocation prioritizes de-leveraging, bolt-on M&A, a small dividend and buybacks. Risks: the global industrial/fabrication cycle; emerging-market currency and macro risk; raw-material (steel, alloys) cost swings versus pricing; competition; and integration risk on acquisitions.

Welding & Cutting: Equipment Plus the Recurring, High-Margin Consumables Core

Welding & Cutting is the heart of ESAB — selected various aggregate the large majority of revenue — and it has two complementary halves. Equipment is the capital-goods half: arc-welding power sources (MIG/MAG, TIG, stick, submerged-arc), wire feeders and torches, plasma and oxy-fuel cutting machines, robotic and automated welding systems, and digital tools (welding-data management, fleet management, training/simulation software) — sold to fabricators, OEMs and contractors; it's the more cyclical, project- and capex-linked piece (customers buy equipment when activity and confidence are high), with growth coming from the automation/digitalization trend (labor shortages of skilled welders push customers toward automated cells) and product refresh. Consumables is the razor-blade half and the prize: filler metals — solid and flux-cored welding wire, covered electrodes, submerged-arc wire and fluxes, hardfacing alloys, brazing/soldering products — that are consumed every time something is welded, producing a recurring revenue stream roughly half-ish of total company revenue, with attractive margins (especially in the higher-spec, alloy-rich and branded segments) and demand tied to the intensity of fabrication activity (tons of steel welded) rather than capex decisions, making it more resilient than equipment. The two reinforce each other: an installed base of ESAB equipment pulls through ESAB consumables; a strong consumables brand and distribution presence supports equipment placement. FY2025 dynamics: solid consumables demand in most regions (emerging-market fabrication activity a tailwind; developed-market general industry mixed), equipment demand tracking the industrial-capex cycle (some softness in spots), pricing actions offsetting raw-material (steel, alloy) and labor inflation, favorable mix toward higher-value products, and EBX-driven cost-outs lifting margins. FY2026 catalyst: global fabrication and construction/infrastructure activity (energy-transition projects — wind, pipelines, LNG, grid — plus reshoring/infrastructure spend are demand drivers), emerging-market growth, pricing/cost spread, the automation/digitalization product cycle, and new-product launches. Risks/competitors: a global industrial downturn (hits both halves, equipment harder); raw-material cost spikes outrunning pricing; currency (a large non-USD revenue base); and a competitive field — Lincoln Electric (LECO, the closest comp, US-centric), Illinois Tool Works' welding segment (ITW — the Miller Electric / Hobart brands), voestalpine Böhler Welding, Fronius (private), Kemppi (private), and a long tail of regional welding-product makers, plus Colfax/Enovis-unrelated cutting players like Hypertherm (private) in plasma cutting.

Gas Control, the EBX Operating System, and the Bolt-On M&A Program

The second leg combines ESAB's diversification engine (Gas Control) with its margin engine (EBX) and its growth lever (M&A). Gas Control — marketed largely under the GCE Group brand — makes the equipment that controls and delivers industrial and specialty gases: pressure regulators, flowmeters, manifolds and gas-distribution systems, cutting and welding torches and gas apparatus, and high-purity/specialty-gas equipment; ESAB has deliberately expanded this from a welding-adjacent gas-apparatus business into a broader specialty- and medical-gas-equipment platform through acquisitions (Ohio Medical — medical suction and oxygen therapy/regulators; Therapy Equipment; Sager S.A. and similar medical-gas businesses; plus welding-automation tuck-ins like SUMIG) — adding faster-growing, less-cyclical, higher-margin healthcare-adjacent revenue (hospital gas systems, oxygen therapy, medical regulators) that diversifies away from pure industrial fabrication. EBX ("ESAB Business Excellence") is the company's lean-operating system — a direct descendant of the Colfax Business System (itself in the Danaher Business System tradition) — a continuous-improvement discipline (kaizen, value-stream mapping, 80/20 simplification, footprint rationalization, procurement, pricing rigor) that ESAB has used since the spin to drive structural margin expansion (adjusted EBITDA margin has climbed steadily, with management targeting further gains toward the low-20s%+) — it's the core of the equity story alongside the consumables annuity. M&A: ESAB runs a disciplined bolt-on acquisition program (specialty/medical gas, welding automation, geographic/product fill-ins), funded by free cash flow and modest debt, integrated via EBX. FY2025 dynamics: Gas Control growing (medical/specialty gas the faster piece), EBX delivering ongoing margin gains, several bolt-ons completed and integrated, leverage coming down. FY2026 catalyst: Gas Control / medical-gas growth, EBX-driven margin progression (toward the company's targets), bolt-on M&A cadence and accretion, and the de-leveraging path freeing up capital for more deals/buybacks. Risks/competitors: medical-gas integration and regulatory (FDA/quality) risk on the healthcare-adjacent businesses; the limits of EBX (margin gains get harder at the margin); overpaying for or mis-integrating acquisitions; and competition in gas control from Air Liquide / Linde (LIN) (captive gas-equipment), Rotarex, Cavagna, and medical-gas players like Amico, Precision Medical, BeaconMedaes (Atlas Copco) and Drägerwerk.

Capital Position + Balance Sheet

ESAB has been steadily strengthening its balance sheet since the spin. It pays a small dividend (selected various aggregate annual dividend per share in the area of $0.30-0.40, a yield roughly ~0.1-0.3% — token, with cash directed at de-leveraging and M&A), conducts opportunistic share buybacks (the ~60M share count is roughly flat-to-slightly-down), and carries net debt of selected various aggregate roughly $0.6-1.2B (term loans, notes and a revolver — used at the spin to capitalize the company and since for acquisitions, but paid down with strong free cash flow), bringing net debt to EBITDA down to around ~1.0-2.5x (from materially higher at the 2022 spin) — a near-investment-grade credit profile (BB+/Ba1-area, on a positive trajectory toward IG) — with ample liquidity. Free-cash-flow conversion is solid given the high-margin consumables mix and modest capex (the businesses are not capital-intensive); the cash priorities are de-leveraging (the headline use post-spin), bolt-on M&A, the small dividend, and buybacks. There is no material pension overhang of consequence at this scale; the principal balance-sheet considerations are the de-leveraging trajectory, the path to an investment-grade rating, the currency translation of the large non-USD operations, and acquired-intangible amortization (which keeps GAAP EPS below adjusted EPS).

Key Core Metrics

• Revenue: selected various aggregate ~$2.6-2.95B FY2025; segments = Americas + EMEA & APAC; products = Equipment, Consumables, Gas Control
• Adjusted EBITDA: selected various aggregate ~$490-570M FY2025; margin ~18-20%+ (expanding)
• Adjusted EPS: selected various aggregate ~$5.00-6.25 FY2025 (GAAP lower on acquired-intangible amortization)
• Consumables (filler metals): ~half-ish of revenue; recurring (consumed per weld); high-margin; tracks fabrication intensity
• Equipment: welding power sources, wire feeders, plasma/oxy-fuel cutting, robotic/automated cells, digital welding software; capex/cycle-linked; automation/digitalization growth
• Gas Control (GCE Group brand): regulators, flowmeters, manifolds, gas apparatus + a growing specialty/medical-gas-equipment platform (Ohio Medical, Sager, etc.)
• EBX ("ESAB Business Excellence"): the lean operating system (Colfax/Danaher lineage) driving structural margin expansion
• Geography: genuinely global; large emerging-market share (Latin America, Middle East, India, Asia, Eastern Europe) — growth tailwind + currency/macro volatility
• End-markets: general fabrication, construction/infrastructure, energy (O&G, pipelines, power, wind), transportation, shipbuilding, repair & maintenance, healthcare (medical gas)
• Organic growth: selected various aggregate ~low-to-mid-single % (volume + price); M&A adds more
• Net debt: selected various aggregate ~$0.6-1.2B FY2025
• Net debt / EBITDA: selected various aggregate ~1.0-2.5x (down sharply since the 2022 spin)
• Credit profile: near-investment-grade (BB+/Ba1-area, positive trajectory toward IG)
• Dividend: selected various aggregate ~$0.30-0.40/share annually (~0.1-0.3% yield; token)
• Buybacks: opportunistic; ~60M shares outstanding (roughly flat-to-slightly-down)
• Capex: modest (businesses not capital-intensive); solid FCF conversion
• Capital allocation: de-leveraging → bolt-on M&A → small dividend → buybacks
• CEO: Shyam Kambeyanda (President & CEO, ~3-4 year tenure since the April 2022 Enovis/Colfax spin-off)

Market Evaluation

At roughly ~$95-150 per share on ~60M shares, ESAB Corporation carries an equity value of selected various aggregate ~$5.5-9.0B (and an enterprise value of selected various aggregate ~$6.5-10.5B including net debt), which puts it around selected various aggregate ~16-26x P/E, ~12-19x EV/EBITDA and ~16-26x EV/FCF with a token ~0.1-0.3% dividend yield — a multiple that has re-rated upward since the spin as ESAB demonstrated EBX-driven margin expansion, de-leveraging and consistent execution, narrowing (but not closing) the discount to its closest comp. The comp set: Lincoln Electric (LECO) is the direct read-through (the US-listed pure-play welding leader, which trades at a premium ESAB is working toward); Illinois Tool Works (ITW) houses a large welding segment (Miller/Hobart); Colfax's other spin-off Enovis (ENOV) and the broader diversified-industrials/quality-compounder set — Dover (DOV), Crane (CR), IDEX (IEX), Ingersoll Rand (IR), Roper (ROP) — provide the EBX/operating-system comparison; and on gas control, Linde (LIN) and Air Liquide (captive), plus medical-gas-adjacent names. FY2026 base case: selected various aggregate ~$2.7-3.05B revenue + ~$5.50-6.75 adj. EPS + ~$510-590M adjusted EBITDA + ~1.0-2.5x net debt/EBITDA + continued EBX margin gains + bolt-on M&A + de-leveraging — steady mid-single-digit growth with margin expansion. Bull case: selected various aggregate ~$2.9-3.3B+ revenue + ~$6.50-8.00+ adj. EPS on strong global fabrication demand (energy-transition and infrastructure projects, emerging-market growth), Gas Control/medical-gas acceleration, EBX pushing the adjusted EBITDA margin into the low-20s%+, accretive bolt-ons, reaching investment grade (lower funding cost), buybacks, and a continued re-rating toward LECO's multiple. Bear case: selected various aggregate ~$2.4-2.7B revenue + ~$4.25-5.25 adj. EPS on a global industrial downturn (equipment demand falling, consumables volumes softening), a steel/alloy cost spike outrunning pricing, emerging-market currency hits, a stalled medical-gas integration, leverage rising on a debt-funded deal, and a multiple de-rating toward the cyclical-industrials average. The thesis turns on the Welding & Cutting pipeline (Equipment + the recurring high-margin Consumables core) plus the Gas Control + EBX + M&A pipeline (gas-equipment and medical-gas growth + the lean-operating-system margin expansion + disciplined bolt-ons) plus the consumables annuity plus a healthy global fabrication/industrial backdrop plus the de-leveraging path toward investment grade plus Shyam Kambeyanda's execution of the post-spin EBX playbook.